In this project, 10 partner institutions (3 research institutions and 7 companies) will work together to prepare for, commence and complete initial clinical development of PRS-080, a novel Anticalin therapeutic for the treatment of anemia of chronic disease (ACD).

All partners have outstanding research and development capabilities in their respective field. Their expertise – as demonstrated by numerous publications and patent applications – will contribute to the success of the project.

Please click on the partners’ names for a brief description of each organization, the contribution each will make to the EUROCALIN project and contact information.